Very low intensity ultrasounds as a new strategy to improve selective delivery of nanoparticles-complexes in cancer cells
Authors:
- Rossella LoriaRLRossella Loria
- Claudia GilibertiCGClaudia Giliberti
- Angelico BediniABAngelico Bedini
- Raffaele PalombaRPRaffaele Palomba
- Giulio CaraccioloGiulio Caracciolo
- Pierpaolo CeciPCPierpaolo Ceci
- Elisabetta FalvoEFElisabetta Falvo
- Raffaella MarconiRMRaffaella Marconi
- Rita FalcioniRFRita Falcioni
- Gianluca BossiGBGianluca Bossi
- Lidia StrigariLSLidia Strigari
Top Cited Papers
Open Access
- 3 January 2019
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-11
Abstract
The possibility to combine Low Intensity UltraSound (LIUS) and Nanoparticles (NP) could represent a promising strategy for drugs delivery in tumors difficult to treat overcoming resistance to therapies. On one side the NP can carry drugs that specifically target the tumors on the other the LIUS can facilitate and direct the delivery to the tumor cells. In this study, we investigated whether Very Low Intensity UltraSound (VLIUS), at intensities lower than 120 mW/cm2, might constitute a novel strategy to improve delivery to tumor cells. Thus, in order to verify the efficacy of this novel modality in terms of increase selective uptake in tumoral cells and translate speedily in clinical practice, we investigated VLIUS in three different in vitro experimental tumor models and normal cells adopting three different therapeutic strategies. VLIUS at different intensities and exposure time were applied to tumor and normal cells to evaluate the efficiency in uptake of labeled human ferritin (HFt)-based NP, the delivery of NP complexed Firefly luciferase reported gene (lipoplex-LUC), and the tumor-killing of chemotherapeutic agent. Specifically, we found that specific VLIUS intensity (120 mW/cm2) increases tumor cell uptake of HFt-based NPs at specific concentration (0.5 mg/ml). Similarly, VLIUS treatments increase significantly tumor cells delivery of lipoplex-LUC cargos. Furthermore, of interest, VLIUS increases tumor killing of chemotherapy drug trabectedin in a time dependent fashion. Noteworthy, VLIUS treatments are well tolerated in normal cells with not significant effects on cell survival, NPs delivery and drug-induced toxicity, suggesting a tumor specific fashion. Our data shed novel lights on the potential application of VLIUS for the design and development of novel therapeutic strategies aiming to efficiently deliver NP loaded cargos or anticancer drugs into more aggressive and unresponsive tumors niche.Keywords
Funding Information
- AIRC (IG2016#18449, IG2017#16776)
This publication has 51 references indexed in Scilit:
- Ultrasound-Targeted Microbubble Destruction to Deliver siRNA Cancer TherapyCancer Research, 2012
- Ultrasound microbubble contrast agent-mediated suicide gene transfection in the treatment of hepatic cancerOncology Letters, 2012
- Advances in Ultrasound Mediated Gene Therapy Using Microbubble Contrast AgentsTheranostics, 2012
- TrabectedinDrugs, 2010
- Toward the Rational Design of Lipid Gene Vectors: Shape Coupling between Lipoplex and Anionic Cellular Lipids Controls the Phase Evolution of Lipoplexes and the Efficiency of DNA ReleaseACS Applied Materials & Interfaces, 2009
- Optical Microscopic Findings of the Behavior of Perflubutane Microbubbles Outside and Inside Kupffer Cells During Diagnostic Ultrasound ExaminationInvestigative Radiology, 2008
- Modeling Transmembrane Transport through Cell Membrane Wounds Created by Acoustic CavitationBiophysical Journal, 2008
- Gene therapy progress and prospects: Ultrasound for gene transferGene Therapy, 2007
- Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumoursThe Journal of Steroid Biochemistry and Molecular Biology, 2006
- Differential sensitivity of liposarcoma subtypes to chemotherapyEuropean Journal of Cancer, 2005